Shots:
- Sanofi has entered into an agreement to acquire Vicebio, expanding its respiratory vaccines pipeline & capabilities with Vicebio’s vaccine candidates (VXB-241 & VXB-251) & Molecular Clamp tech
- As per the deal, Vicebio will receive $1.15B upfront & ~$450M in development & regulatory milestones; closing is expected in Q4’25
- Molecular Clamp tech stabilizes viral proteins in their native form to enhance immune recognition, allowing rapid development of fully liquid combination vaccines that require only standard refrigeration, whereas VXB-241 is a P-I bivalent vaccine targeting RSV as well as hMPV & VXB-251 is a preclinical trivalent vaccine targeting RSV, hMPV & parainfluenza virus Type 3
Ref: Sanofi | Image: Vicebio | Press Release
Related News:- Libertas Bio Licenses Gusacitinib to Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
